Archived explainer. For the current picture see today's GOSS page.
GOSSAMER BIO INC (GOSS) is drawing unusual attention today. Our newswire has captured 5 stories on GOSS across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
GOSS stock is moving higher today after the company announced a regulatory update from the FDA and the reacquisition of worldwide rights to its lead drug candidate, seralutinib. The stock opened at $0.13, down slightly from the prior close, but quickly reversed to trade as high as $0.21 during the session. The move follows a series of disclosures regarding the company's capital structure and drug development progress, which have bolstered investor confidence.
Gossamer Bio announced that the FDA has outlined a path toward a September 2026 NDA filing for seralutinib, a key development in its regulatory timeline. In addition, the company regained full global rights to the drug, a strategic win that removes licensing constraints and allows for broader commercialization potential. These developments were accompanied by a strengthening of the company’s capital structure, including investor approvals and a $57 million cash position reported after securing stockholder approval for a convertible note exchange and reverse stock split. The news has triggered a sharp intraday rebound in the stock, which is now trading near $0.19.
The stock has traded in a wide range today, from $0.13 at the open to a high of $0.21. Volume has surged to 253 million shares, significantly above the 3-month average. While the stock has declined 17% over the past 8 sessions, today’s rally suggests a potential reversal in sentiment. The stock is currently trading within its 52-week range of $0.11 to $3.87, though it remains well below its peak. The company’s fundamentals remain challenging, with a market cap of $66.5 million and a trailing twelve-month net margin of -324.8%.
The company has not announced an upcoming earnings date, but coverage breadth is expanding with five stories from five sources in the last 36 hours. Investors will likely monitor regulatory developments and capital structure updates for further clarity on the path forward.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates July 27, 2026 8:00 AM EDTCompany...
Gossamer Bio firms up its future with a clear FDA submission timeline for seralutinib, reacquires worldwide rights to the drug, and reinforces its capital structure following major investor approvals and convertible note exchanges.
Gossamer Bio (NASDAQ:GOSS) shares jumped after the FDA outlined a path toward a September NDA filing for seralutinib and the company regained worldwide rights to the therapy while reducing its debt.
Why is Gossamer Bio stock surging today?
More on GOSS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GOSS move explainers: 2026-07-28 · 2026-07-27